Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Putting the Bully in the Bully Pulpit: The Democrats' Plan to Cut Drug Prices

This article was originally published in RPM Report

Executive Summary

Legislation to force price negotiation under Medicare Part D is likely to end in a stalemate. But manufacturers can't afford to relax: the Democrats plan to turn up the pressure even if a law never passes. First they will compare Part D prices to other benchmarks. Then the bullying begins.

You may also be interested in...



The Bully Pulpit: Trump Versus Drug Prices

Medicare price negotiation is not a new idea – nor is the concept of using the Presidential megaphone to talk down drug prices. Will Trump and Twitter turn it into something bigger?

The Campaign Against Drug Pricing: Candidates Can Only Hope Voters React As Strongly As Wall Street

Wall Street remains hypersensitive to threats from Washington or the campaign trail to take action to limit prescription drug pricing. But it is still hard to see why the threat is any greater because the Clinton campaign has a “plan” to address the issue.

When Empty Threats Work: “Price Negotiation” In White House Budget Spooks Wall Street

Investors remain hyper-sensitive to any threat to pricing flexibility for biotech products. The latest over-reaction – to a renewed call for Medicare “price negotiation” – meant missing some of the more meaningful messages coming from Washington about support for innovation.

Related Content

Topics

UsernamePublicRestriction

Register

PS080220

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel